70results about How to "Low metastatic" patented technology

The invention relates to a material laminate for use as a covering sheet on absorbent articles such as sanitary napkins, incontinence protectors, diapers, pant diapers, or the like. The material laminate comprises a first, fluid pervious fibrous material layer and a second fluid pervious porous material layer, wherein at least one of the two material layers comprises thermoplastic material and wherein the two material layers are mutually connected by means of the covering material laminate exhibiting bond sites within which the thermoplastic material has been caused to at least partially soften or melt and thereby bond the two material layers together. In the planar extension, the material laminate exhibits two side portions extending in the length direction and having an extension in the width direction from a respective longitudinal side edge and a distance in towards the longitudinal central axis of the material laminate and a central portion positioned between the side portions in the planar extension of the material laminate, wherein the first material layer and the second material layer in the central portion of the material laminate are intermittently bonded together with a first bond pattern and that the first material layer and the second material layer in the two side portions of the material laminate are intermittently bonded together with a second bond pattern wherein the percentage bonded area in relation to the total area in the two side portions is greater then the percentage bonded area in relation to the total area in the central portion. The invention further pertains to an absorbent article comprising the material laminate.

A method is proposed for controlling and / or regulating a starting process in a hybrid drive arrangement of a vehicle, in which at least one control unit (8) is used by means of which a combustion engine (1), at least one electric machine (3), a transmission (4) and a first clutch (2) arranged between the combustion engine (1) and the electric machine (3) and a second clutch (5) arranged between the electric machine (3) and the transmission (4) are controlled so as to carry out a starting process, such that to change from electric starting to at least partially combustion-engine-powered staring the clutch torque that can be transferred is adjusted to the nominal driving torque so that the torque of the electric machine (3), the torque of the combustion engine (1) and / or the clutch torque of the first clutch (2) are matched. In addition a hybrid drive arrangement of a vehicle with at least one control unit (6) is proposed, by means of which a combustion engine (1), at least one electric machine (3), a transmission (4) and a first clutch (2) arranged between the combustion engine (1) and the electric machine (3) and a second clutch (5) arranged between the electric machine (3) and the transmission (4) can be controlled so as to carry out a starting process, such that to change from electric starting to at least partially combustion-engine-powered staring the clutch torque that can be transferred by the second clutch (5) is adjusted to the nominal driving torque so that the torque of the electric machine (3), the torque of the combustion engine (1) and / or the clutch torque of the first clutch (2) can be matched.

The invention discloses a class of electroluminescent materials, a preparation method and applications thereof. According to the present invention, the sulfur oxygen fluorine and benzene unit is a seven-membered fused ring structure, wherein the good planarity easily achieves the injection and transport of carriers, and improves the photoelectric properties of the material; the bicyclic structurecan make the sulfur oxygen fluorine and benzene unit have good rigidity so as to easily improve the heat resistance of the material and meet the practical needs of the materials; and the electroluminescent material based on the sulfur oxygen fluorine and benzene unit and obtained through Suzuki coupling reaction, Ullmann coupling reaction, still coupling reaction and the like has good solubility,can be dissolved with common organic solvents, can form a film through spin coating, ink jet printing or printing, and can be prepared into the light emitting layer of light-emitting diodes.

The invention relates to a cigarette capable of highlighting aroma of the first puff and a manufacturing method thereof. Starting from selecting novel cigarette spice and selecting the application portion, it is ensured that precursor-aroma spice is added to the front end of the cigarette in the mode of dip coating, or spray coating or coining, and the cigarette product with the spice added to the front end is prepared. Spice applying stability and targeted release are improved through the mode, it is ensured that aroma of the first puff is enhanced in an oriented mode in the cigarette puffing process, the style is highlighted, the defects that a common cigarette product is weak in aroma of the first puff, strong in impurity gas and high in irritation and dry sensation are overcome, and the quality of the cigarette product is promoted.

The invention discloses application of a human GTPBP4 gene and related drugs of the human GTPBP4 gene. The invention discloses application of the human GTPBP4 gene in tumor treatment, tumor diagnosis and drug preparation. The invention further constructs human GTPBP4 gene small interference RNA, a human GTPBP4 gene interference RNA constructor and a human GTPBP4 gene interference lentivirus and also discloses applications of the human GTPBP4 gene small interference RNA, the human GTPBP4 gene interference RNA constructor and the human GTPBP4 gene interference lentivirus. The siRNA or the RNA constructor or the lentivirus containing the sequence of the siRNA provided by the invention can specifically inhibit the expression of the human GTPBP4 gene, and especially, the lentivirus can effectively infect a target cell and effectively inhibit the expression of GTPBP4 gene in the target cell, so that the growth of tumor cells is inhibited and tumor cell apoptosis is promoted; therefore, the invention is of great significance in the treatment of tumors.

The invention discloses applications of human PTP4A3 gene and related drugs thereof. Applications of human PTP4A3 gene in tumor treatment, tumor diagnosis, and drug preparation are disclosed. The invention further constructs human PTP4A3 gene micromolecule interference RNA, human PTP4A3 gene interference nucleic acid construct, and human PTP4A3 gene interference slow virus, and discloses the applications thereof. The provided siRNA or nucleic acid construct containing the siRNA and slow virus can inhibit the expression of human PTP4A3 gene specifically, especially the slow virus can infect target cells efficiently and inhibit the expression of PTP4A3 gene in target cells efficiently, thus the tumor cell growth is inhibited, apoptosis of tumor cells is promoted, and thus the provided siRNA, nucleic acid construct, and slow virus have an important meaning in tumor treatment.

The invention discloses the use of a human TNFRSF12A gene and related drugs. The invention discloses the use of the human TNFRSF12A gene in tumor therapy, tumor diagnosis and drug preparation. The invention further constructs human TNFRSF12A gene small interfering RNA, a human TNFRSF12A gene interference nucleic acid construct, and a human TNFRSF12A gene interference slow virus and discloses their use. The siRNA or the nucleic acid construct containing the siRNA sequence, and the slow virus provided by the invention can specifically inhibit the expression of the TNFRSF12A gene, especially the slow virus can efficiently infect target cells, effectively inhibit the expression of the TNFRSF12A gene in the target cells, and therefore inhibits the growth of tumor cells and promotes tumor cell apoptosis, thus having important significance in tumor treatment.

The invention belongs to the field of biotechnology, and relates to a novel medicinal use of a thrombin inhibitor, in particular to a use of the thrombin inhibitor, especially a bivalent direct thrombin inhibitor in the preparation of an anti-tumor invasion and metastasis drug. The direct thrombin inhibitor short peptide DTIP with anticoagulant activity is adopted to carry out an in vitro cell test and an in vivo animal experiment, and a test result shows that the bivalent direct thrombin inhibitor DTIP can inhibit tumor invasion and metastasis in vitro; the in vivo experiment shows that the bivalent direct thrombin inhibitor DTIP has an impact on tumorigenesis and development; and further, the direct thrombin inhibitor DTIP can be used for preparing the anti-tumor invasion and metastasisdrug.

A morphing skin for an air vehicle structure, the skin being formed by a composite material which includes: a multiplicity of fibres, a matrix incorporating the fibres, and a thermo-sensitive material, such as a thermo-plastic. The thermo-sensitive material can be reversibly transitionable in response to a change in temperature, between (i) an ambient temperature mode in which the thermo-sensitive material is capable of transferring loads in the composite material, and (ii) a heated mode in which the ability of the thermo-sensitive material to transfer the loads is reduced. This can allow the stiffness of the skin to be temporarily reduced to enable the skin to be morphed into a different shape.

The invention discloses applications of human DGKZ gene and related drugs thereof. Applications of human DGKZ gene in tumor treatment, tumor diagnosis, and drug preparation are disclosed. The invention further constructs human DGKZ gene micromolecule interference RNA, human DGKZ gene interference nucleic acid construct, and human DGKZ gene interference slow virus, and discloses the applications thereof. The provided siRNA or nucleic acid construct containing the siRNA and slow virus can inhibit the expression of human DGKZ gene specifically, especially the slow virus can infect target cells efficiently and inhibit the expression of DGKZ gene in target cells efficiently, thus the tumor cell growth is inhibited, apoptosis of tumor cells is promoted, and thus the provided siRNA, nucleic acid construct, and slow virus have an important meaning in tumor treatment.

The invention discloses application of a human TRIP13 gene and a related medicine thereof, discloses application of the human TRIP13 gene in preparation of tumor treatment medicines, further establishes small interfering RNA (ribonucleic acid) of the human TRIP13 gene, an interfering RNA builder of the human TRIP13 gene and an interfering chronic virus of the human TRIP13 gene, and discloses application thereof. The siRNA or the RNA builder and chronic virus containing the siRNA sequence can be used for specifically inhibiting the expression of the human TRIP13 gene; especially, the chronic virus can efficiently infect the target cell, the expression of the TRIP13 gene in the target cell can be inhibited at high efficiency, the growth of the tumor cell is further inhibited, the withering of the tumor cell is promoted, and the important significance is realized in tumor treatment.

The invention discloses uses and related drugs of a human RBM17 gene. The invention discloses the uses of the human RBM17 gene in tumor therapy, tumor diagnosis and drug preparation. The invention further discloses a human RBM17 gene small-molecular interference RNA, a human RBM17 gene interference nucleic acid construction body and a human RBM17 gene interference slow virus and uses thereof. The siRNA or the siRNA sequence-containing nucleic acid construction body and slow virus provided by the invention, especially the slow virus, can specifically inhibit expression of the human RBM17 gene, can efficiently infect target cells, efficiently inhibit expression of the RBM17 gene in the target cells, inhibit the growth of the tumor cells, promote the apoptosis of the tumor cells and have important significance in tumor therapy.

The invention relates to the technical field of ovarian cancer treatment, and discloses a pharmaceutical composition used for treating ovarian cancer and application thereof. The pharmaceutical composition used for treating ovarian cancer contains kaempferol and celastrol as active components. In the pharmaceutical composition used for treating ovarian cancer, the kaempferol and the celastrol areused in combination, wherein the kaempferol is capable of significantly enhancing antitumor effects of the celastrol by the effects of blocking cell cycles, inducing apoptosis, inhibiting cell proliferation, inhibiting cell migration and the like; and thus, the kaempferol and the celastrol synergistically take a significant effect in inhibiting growth of ovarian cancer cells.

The invention discloses application of a human DGKZ gene and related drugs thereof. The invention discloses application of the human DGKZ gene in tumor treatment, tumor diagnosis and drug preparation.The invention further constructs a human DGKZ gene small interfering RNA, a human DGKZ gene interfering nucleic acid construct and a human DGKZ gene interfering lentivirus, and discloses applicationsof the siRNA, the interfering nucleic acid construct and the interfering lentivirus. The siRNA or the nucleic acid construct containing the siRNA sequence, and the lentivirus provided by the invention can specifically inhibit the expression of the human DGKZ gene. Especially, the lentivirus can efficiently infect target cells, efficiently inhibit the expression of DGKZ genes in the target cells,further inhibit the growth of tumor cells and promote the apoptosis of the tumor cells, and has important significance in tumor treatment.

The invention discloses an application of human EIF3A gene and related drugs. The invention discloses an application of the human EIF3A gene in tumor therapy, tumor diagnosis and drug preparation. The invention also further constructs human EIF3A gene small interfering RNA, human EIF3A gene interfering nucleic acid construct and human EIF3A gene interfering lentivirus and discloses their applications. The siRNA or the nucleic acid construct and lentivirus containing the siRNA sequence can specifically inhibit expression of the human EIF3A gene, especially lentivirus can efficiently infect target cell and efficiently inhibit expression of the EIF3A gene in the target cell so as to further inhibit growth of tumor cells and promote tumor cell apoptosis. Thus, the invention is of great significance in tumor therapy.

The invention discloses uses and relevant drugs of human RPL34 (ribosomal protein L34) gene. The invention discloses the uses of the human RPL34 gene in tumor treatment, tumor diagnosis and drug preparation. The invention further constructs small molecule interfering RNA of the human RPL34 gene, an interfering nucleic acid construction body of the human RPL34 gene, interfering lentivirus of the human RPL34 gene, and discloses the uses thereof. The siRNA (small interfering RNA) or the nucleic acid construction body containing the siRNA sequence and the lentivirus provided by the invention can specifically inhibit the expression of the human RPL34 gene, and particularly the lentivirus can efficiently infect target cells and efficiently inhibit the expression of the RPL34 gene in target cells so as to inhibit the growth of tumor cells and promote the apoptosis of the tumor cells, and has vital significance in the tumor treatment.

The present invention relates to a hair straightening apparatus having two arms pivotably coupled together and a heating plate on a facing side of at least one arm. A flexible protective rim substantially surrounds the periphery of a hair contacting surface of each heating plate.

The invention discloses a traditional Chinese medicine composition for treating cancer and a preparation method thereof. The traditional Chinese medicine composition comprises oldenlandia diffusa, sculellaria barbata, taraxacum mongolicum, bunge corydalis herb, radix sophorae tonkinensis, common andrographis herb, folium mori, semen coicis, corns, millet and honey according to certain weight ratio. The traditional Chinese medicine composition has the efficacies of eliminating cancer, clearing heat and detoxicating, eliminating carbuncle and removing stasis, dissolving stasis and stopping pain, strengthening the body resistance and eliminating pathogenic factors as well as treating cancer with medicaments and food and can be used for effectively treating cancer.

The invention relates to new application of a traditional Chinese medicine, in particular to application of total glycoside of paeonia in preparation of a medicament for treating thyroid cancer and improving tumor radiotherapy synergy, and belongs to the technical field of traditional Chinese medicines. The invention relates to the application of total glycoside of paeonia in preparation of a medicament for treating thyroid cancer and improving tumor radiotherapy synergy. The total glucosides of paeonia can be used as an active ingredient, are added with pharmaceutically-acceptable pharmaceutical excipients or carriers, and are prepared into a preparation according to a method recorded in pharmacy. The total glycosides of paeonia of the invention can also be used as one of the active ingredients, also contain other medicines, are added with pharmaceutically-acceptable pharmaceutical excipients or carriers, and are prepared into a preparation according to the method recorded in pharmacy. Through research, the inventor discovers that: the total glucosides of paeonia have obvious functions of resisting thyroid cancer and enhancing iodine uptake of cancer cells, and can improve the sensitivity of radiotherapy, can be prepared into a medicament for treating thyroid cancer, and can be prepared into a medicament for improving tumor radiotherapy synergy.

The invention discloses a printable anti-scratch anti-static protective film which sequentially comprises a printable anti-scratch coating, an optical PET base material layer, a modified anti-static layer and a non-silicon release film layer from top to bottom, wherein the printable anti-scratch coating is made of polyurethane, and the modified anti-static layer is an anti-static polyurethane adhesive layer. The invention also discloses a preparation method of the printable anti-scratch anti-static protective film, which comprises the following steps of: coating one surface of an optical PET base material layer with printable anti-scratch coating liquid on line, coating the other surface of the optical PET base material layer with anti-static polyurethane glue after the coating is cured and dried, baking the product in a baking oven, taking the product out of the baking oven, attaching a non-silicon release film on line, and rolling and pulling the product into an oven for curing to obtain the printable anti-scratch anti-static protective film. The anti-scratch anti-static film has a very good anti-scratch effect, and the phenomenon of local anti-static instability caused by fogging and uneven coating of the anti-static film is avoided.

The invention relates to application of a human PLEKHO1 gene and related medicines thereof, and discloses application of the human PLEKHO1 gene in tumor treatment and medicine preparation. A human PLEKHO1 gene small interfering RNA, a human PLEKHO1 gene interfering nucleic acid constructor and human PLEKHO1 gene interfering lentivirus are further constructed, and application of the human PLEKHO1 gene small interfering RNA, the human PLEKHO1 gene interfering nucleic acid constructor and the human PLEKHO1 gene interfering lentivirus are disclosed. The siRNA or the nucleic acid constructor containing the siRNA sequence and the lentivirus can specifically inhibit the expression of the human PLEKHO1 gene, especially the lentivirus, can efficiently infect target cells, efficiently inhibits the expression of the PLEKHO1 gene in the target cells, then inhibits the growth of tumor cells, promotes tumor cell apoptosis and has important significance in tumor treatment.

The invention discloses an application of a human IARS2 gene and related medicines thereof. The invention discloses the application of the human IARS2 gene to tumor therapy, tumor diagnosis and medicine preparation. The invention also further constructs human IARS2 gene siRNA (small interfering ribonucleic acid), a human IARS2 gene interfering nucleic acid construct and a human IARS2 gene interfering lentivirus and discloses applications of human IARS2 gene siRNA, the human IARS2 gene interfering nucleic acid construct and the human IARS2 gene interfering lentivirus. The siRNA provided by the invention or the nucleic acid construct and lentivirus containing the sequence of siRNA can specifically inhibit expression of the human IARS2 gene, in particular, the lentivirus can efficiently infect target cells and efficiently inhibit expression of the IARS2 genes in the target cells and then inhibit growth of tumor cells and promote tumor cell apoptosis and has great significance in tumor therapy.

Provided is a mold release film which has good releasability from an adhesive and is extremely suppressed in oligomer precipitation, while being suppressed in migration, and which is suitable for various adhesive layer protection applications for the production of a capacitive touch panel, the production of LCD constituent members such as a polarizing plate and a retardation film used for a liquid crystal display (LCD), the production of a plasma display panel constituent member, the production of an organic electroluminescent display constituent member, the production of various display constituent members, and the like. A mold release film that is characterized by having a silicone-based mold release layer, which is formed from a coating liquid containing a reactive silicone resin having a functional group, an unreactive silicone resin and a platinum-based catalyst, on one surface of a polyester film.

The invention discloses a class of electroluminescent materials and a preparation method and application thereof. Among them, the thioxafluorene unit is a seven-membered condensed ring structure, and the better planarity is conducive to the injection and transport of carriers, and improves the optoelectronic properties of the material; , which is beneficial to improve the thermal resistance of the material and meet the practical needs of the material. The present invention obtains the electroluminescent material based on the thioxafluorene unit through Suzuki coupling reaction, Ullman coupling reaction, still coupling reaction, etc., and has good solubility, and can be dissolved in common organic solvents, The light emitting layer of the light emitting diode is prepared by spin coating, ink jet printing or film formation.

The invention discloses the use of human BTG3 gene and related medicines. The invention discloses the application of human BTG3 gene in the preparation of tumor treatment medicine. The present invention further constructs human BTG3 gene small molecule interference RNA, human BTG3 gene interference nucleic acid construct, human BTG3 gene interference lentivirus and discloses their applications. The siRNA provided by the present invention or the nucleic acid construct containing the siRNA sequence, and the lentivirus can specifically inhibit the expression of the human BTG3 gene, especially the lentivirus, which can efficiently infect target cells and efficiently inhibit the expression of the BTG3 gene in the target cells , and then inhibit the growth of tumor cells and promote the apoptosis of tumor cells, which is of great significance in tumor therapy.

The present invention belongs to the field of biotechnology, and relates to a new target for inhibiting the metastasis of bladder cancers, and applications thereof. According to the invention, bladder cancer T24T cells and bladder cancer UMUC3 cells are used as models, and the metastasis of bladder cancer cells can be reduced in vitro and in vivo by inhibiting the expression of miR-3648, such that the miR-3648 expression inhibitor can inhibit the metastasis of bladder cancers; by using a real-time fluorescence quantitative PCR technology, a bioinformatics analysis TCGA database and other methods, the detection results show that the miR-3648 expression in most of the clinical high-grade invasive bladder cancer tissues is significantly up-regulated, such that the miR-3648 expression detection results show that the miR-3648 expression is closely related to the high-grade invasive bladder cancers; and the new target and the corresponding measures can be expected to be provided for the inhibition of the metastasis of bladder cancers.

The invention discloses application of a human GTPBP4 gene and related drugs of the human GTPBP4 gene. The invention discloses application of the human GTPBP4 gene in tumor treatment, tumor diagnosis and drug preparation. The invention further constructs human GTPBP4 gene small interference RNA, a human GTPBP4 gene interference RNA constructor and a human GTPBP4 gene interference lentivirus and also discloses applications of the human GTPBP4 gene small interference RNA, the human GTPBP4 gene interference RNA constructor and the human GTPBP4 gene interference lentivirus. The siRNA or the RNA constructor or the lentivirus containing the sequence of the siRNA provided by the invention can specifically inhibit the expression of the human GTPBP4 gene, and especially, the lentivirus can effectively infect a target cell and effectively inhibit the expression of GTPBP4 gene in the target cell, so that the growth of tumor cells is inhibited and tumor cell apoptosis is promoted; therefore, the invention is of great significance in the treatment of tumors.